Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 370.00
Bid: 360.00
Ask: 380.00
Change: -10.00 (-2.63%)
Spread: 20.00 (5.556%)
Open: 378.00
High: 378.00
Low: 370.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Zegona profit sinks; Flowtech Fluidpower suffers loss

Tue, 20th Apr 2021 12:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Zegona Communications PLC - acquires businesses in European telecommunications, media and technology sector - Posts pretax profit of EUR14.0 million in 2020, falling 67% from EUR42.1 million in 2019. Finance income plummets to EUR3.8 million from EUR38.2 million. "The principal reason for the movement compared to 2019 was that 2019 included a EUR28 million gain on the investment in Euskaltel and EUR10 million dividend from Euskaltel before it was accounted for as an associate," explains Zegona. Investee Euskaltel is a telecommunications provider in the North of Spain. Zegona to pay 4.6p per share to shareholders for 2020, down 8.0% from 5.0p for 2019. Zegona is the leading shareholder in Euskaltel and has two board seats. Euskaltel "expects significant further growth in 2021, both in terms of customer numbers and revenue".

----------

Aquila European Renewables Income Fund PLC - renewable energy infrastructure investor - Reports net asset value per share at December 31 of 99.96 euro cents, down 2.7% from 102.7 cents a year prior. Net assets double to EUR316.9 million from EUR158.9 million. Declares dividend of 4.0 cents per share for 2020, up from 1.5 cents for 2019 and in line with its dividend target of 4.0 cents. Aims to increase dividend target to 5.0 cents per share in 2021. Says its investment strategy is unchanged, and it will continue to invest in renewable energy projects in Europe and the UK. Notes continuing uncertainty caused by Covid-19.

----------

RBG Holdings PLC - London-based law firm - Post pretax profit for 2020 of GBP7.7 million, up 1.3% from GBP7.6 million the year prior. Revenue increases 13% to GBP22.4 million from GBP19.9 million. Personnel costs increase to GBP17.9 million from GBP11.5 million. Pays dividend of 3 pence per share for year. "Based on current outlook, we expect to pay up to 60 per cent of retained earnings in the 2021 financial year by way of dividend," says RBG. "The business will benefit from life post-Brexit and post-Covid as businesses return to normality. Our litigation finance business, LionFish is now established, and we expect the number of cases it invests in to grow, with the first return expected in the first half. With a strong pipeline of deals, and increased interest in [mergers & acquisitions] in 2021, Convex Capital is expected to perform well," says RBG. Convex Capital is a specialist provider of sell-side only M&A advice to UK, US and European entrepreneurs.

----------

Flowtech Fluidpower PLC - Cheshire, England-based valves and hydraulic components maker - Posts pretax loss for 2020 of GBP2.1 million, swinging from a GBP4.7 million profit a year prior. Revenue falls 15% to GBP95.1 million from GBP112.4 million. "With hindsight, there are areas that we could have improved on, particularly around the pace with which we have been able to extract cost from our order, pick and drop activities, that will be essential to our future success...However, we end 2020 having made progress in creating the platform that will ensure our future growth," says Flowtech. Does not declare dividend, but says it remains "keen to reintroduce a final payment for the financial year 2021, and thereafter adopt a balanced approach to dividend policy". "We have been encouraged by our performance over the past quarter, with both revenue and margins trending slightly above our expectations. The combination of Brexit and Covid-19, and in particular the current challenged nature of global supply chains, continue to make underlying trading difficult to interpret. What is clear is there has been a continued upward trend in our 'resellers' business, and evidence of restocking in our OEM customers," says Flowtech. Says if current trading continue, company could exit 2021 with similar revenue to 2019.

----------

MaxCyte Inc - Maryland-based cell and gene therapies firm - Posts net loss of USD11.8 million in 2020, narrowing 8.5% from USD12.9 million the year prior. Revenue increases 21% to USD26.2 million from USD21.6 million. Says it has never declared or paid common stock dividends and has no plans to do so in the foreseeable future. "We expect strong revenue growth in 2021, driven by the continuing progress of our existing strategic partners into and through the clinic and subsequent generation of increased milestone revenues. We are also confident that throughout the coming year we will continue to build our customer base and continue to secure further high-value licensing agreements, driving ongoing growth. The strategic partnership pipeline coming into 2021 is the largest that the company has experienced to date," says MaxCyte.

----------

discoverIE Group PLC - Guildford-based designer, manufacturer and supplier of customised electronics - Says trading momentum in the final two months of the year, to March 31, has continued to strengthen, and the company now expects underlying earnings for the full year to be above the upper end of market expectations. Says sales in the second half were 9% ahead of the first half with a return to organic growth of 1% in the last two months of the year. Sales for the full year were 3% lower, down 6% organically. "The strong order book and momentum provide a solid base for sustained organic sales growth whilst further investing in growth initiatives," says company.

----------

Filta Group Holdings PLC - AIM-listed provider of fryer management - Swings to pretax loss of GBP866,231 in 2020 from a GBP936,284 profit a year prior. Revenue falls 34% to GBP16.4 million from GBP24.9 million. Does not declare a final dividend, compared to 1.0p per share a year before. Says that "provided the progress that has been made in the first quarter of the year continues, it fully expects to be able to resume the payment of dividends in respect of 2021". Says that the upward trend in business levels that the company saw in the second half of 2020 has continued into the current year, with the numbers of new customers in both of its markets, the UK and North America, being particularly encouraging. "With the lockdown restrictions expected to be lifted further over the next two to three months and with the vaccination programmes progressing well in the UK and US, the board is confident that the progress that we have seen in the first quarter will continue through the year and, moreover, that the group is emerging from a highly challenging time much stronger operationally and in robust financial health," says Filta.

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Posts pretax loss for 2020 of GBP717,534, widening from GBP638,654 in 2019. Administrative expenses increase 5.4% to GBP933,462 from GBP885,757. Revenue falls 6.4% to GBP255,314 from GBP272,867. Declares no dividend for 2020, unchanged from 2019. Says the top priority going forward is to "increase in sales and distribution of its advanced imaging solutions".

----------

J Smart & Co (Contractors) PLC - Edinburgh-based construction contractor - Posts pretax profit for the first half to end-January of GBP890,000, widening from GBP265,000 a year before. Revenue falls 38% to GBP5.8 million from GBP9.3 million. Cost of sales halve to GBP5.3 million from GBP10.0 million. Announces an interim dividend of 0.95p per share, flat with the year prior. "We have substantially less work in hand in contracting than the same time last year. It is by no means certain that new contracting work will be secured this financial year due to general delays caused by the coronavirus pandemic," says J Smart. Says it is difficult to give accurate guidance due to uncertainties, but the company does not expect underlying profit to increase this financial year.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Aug 2023 14:26

TRADING UPDATES: MaxCyte strikes deal; Barkby sells Workshop

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
10 Jul 2023 14:05

MaxCyte inks deal with Vittoria Therapeutics for cellular therapies

(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies.

Read more
10 Jul 2023 13:20

MaxCyte signs licence deal with Vittoria Biotherapeutics

(Sharecast News) - MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.

Read more
6 Jul 2023 14:49

MaxCyte inks platform licensing deal with Lyell

(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.

Read more
6 Jul 2023 13:58

MaxCyte inks strategic platform license with Lyell Immunopharma

(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company.

Read more
11 May 2023 12:10

MaxCyte revises guidance after weaker first quarter

(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.

Read more
11 May 2023 10:26

MaxCyte revenue declines, operating loss widens as costs increase

(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher.

Read more
4 May 2023 17:26

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.

Read more
3 May 2023 14:50

UK earnings, trading statements calendar - next 7 days

Thursday 4 May 
Apax Global Alpha LtdQ1 Results
BAE Systems PLCTrading Statement
Cardiff Property PLCHalf Year Results
Derwent London PLCTrading Statement
e-Therapeutics PLCFull Year Results
Glanbia PLCQ1 Results
IMI PLCTrading Statement
Mondi PLCTrading Statement
Morgan Sindall Group PLCTrading Statement
Next PLCTrading Statement
Rathbones Group PLCTrading Statement
Shell PLCQ1 Results
Spirent Communications PLCTrading Statement
Trainline PLCFull Year Results
Virgin Wines UK PLCHalf Year Results
Wheaton Precious MetalsQ1 Results
Friday 5 May 
Eqtec PLCFull Year Results
InterContinental Hotels Group PLCTrading Statement
International Consolidated Airlines Group SAQ1 Results
Monday 8 May 
no events scheduled 
Tuesday 9 May 
Kosmos Energy LtdQ1 Results
Tialis Essential IT PLCFull Year Results
Treatt PLCHalf Year Results
Wednesday 10 May 
Anexo Group PLCFull Year Results
Asos PLCHalf Year Results
Compass Group PLCHalf Year Results
Directa Plus PLCFull Year Results
Georgia Capital PLCQ1 Results
MaxCyte IncQ1 Results
Spirax-Sarco Engineering PLCTrading Statement
Valeura Energy IncQ1 Results
Vertu Motors PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
30 Mar 2023 16:03

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.

Read more
28 Mar 2023 13:03

MaxCyte installs Douglas Swirsky as its new finance chief

(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.

Read more
28 Mar 2023 10:44

MaxCyte appoints new chief financial officer, effective immediately

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.

Read more
16 Mar 2023 15:01

MaxCyte expecting strong 2023 after decent results

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

Read more
16 Mar 2023 12:20

MaxCyte revenue up as growth expected in 2023; net loss widens

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023.

Read more
8 Mar 2023 18:14

IN BRIEF: MaxCyte names members of new scientific advisory board

MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.